‘Three-parent’ children? FDA admonishes fertility company, blocks procedure

| | August 11, 2017
p m x
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

On [August 4], regulators issued a sternly worded letter to fertility doctor John Zhang, who helped a mother with a genetic disorder give birth to a healthy baby boy by using a procedure that combines DNA from her, her husband and an egg donor.

The FDA says that’s not allowed. Since 2015, Congress has forbidden the FDA from accepting submissions for clinical investigations that involve intentionally creating a human embryo with a heritable genetic modification. But Zhang’s research does just this.

The letter notes that Zhang […] had already agreed not to create any more “three-parent” embryos in the United States, but the letter takes issue with the company’s continued marketing of the service.

While the technology was originally used to avoid a disease passed through mitochondria, organelles that are passed down through the egg cell, Zhang’s clinic was hoping to use it for another purpose — to help women of advanced maternal age who had been unable to conceive in other ways. By using an egg from a younger donor combined with their own DNA, the women would theoretically be able to have their own genetic offspring.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: FDA cracks down on company marketing ‘three-parent’ babies

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend